𝔖 Bobbio Scriptorium

✦ LIBER ✦

495 oral FIVE-YEAR SURVIVAL IN A RANDOMIZED PHASE III TRIAL OF CONCURRENT RADIOCHEMOTHERAPY WITH 5-DAY VERSUS WEEKLY CISPLATIN IN LOCALLY ADVANCED CERVICAL CANCER

✍ Scribed by V. Nagy; C. Ordeanu; N. Todor; O. Coza; A. Rancea

Book ID: 119519232
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 30 KB
Volume: 99
Category: Article
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(11)70617-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy in high burden locally advanced

Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: Prognostic and predictive factors and the impact of disease stage on outcomes from a prospective randomized phase III trial

✍ A. Dueňas-González; M. Orlando; Y. Zhou; M. Quinlivan; H. Barraclough 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 603 KB

10-year long-term survival (LTS) of indu

10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45Gy (1.5Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)—A multicenter phase-II trial (CISTAXOL)

✍ Eberhardt, Wilfried Ernst Erich; Gauler, Thomas Christoph; LePechoux, Cecile; St 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 824 KB

353 Oral Phase III multicenter randomize

353 Oral Phase III multicenter randomized study of concurrent twice-a-day continuous radiotherapy with and without Cisplatin-5FU chemotherapy (BiRCF) in locally advanced unresectable pharyngeal squamous-cell carcinoma. Preliminary results regarding feasibility, early tolerance and control at 6 months (FNCLCC-GORTEC)

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 137 KB